April 6, 2011
Gilead Raises Prices of HIV Drugs Atripla, Truvada, Emtriva
Gilead Sciences increased the prices of its top-selling HIV treatment drugs, Bloomberg Businessweek reports. Atripla increased by 5.1 percent, and Truvada and Emtriva increased by 7.9 percent. These jumps are in addition to increases of 12 percent for Atripla and 13 percent for Truvada and Emtriva that occurred between the first quarter of 2009 to the fourth quarter of 2010. Michael Weinstein, president of AIDS Healthcare Foundation, said these price hikes are unreasonable, especially since these drugs have no new formulations and the increases will harm cash-strapped programs such as Medicare.
To read the Businessweek article, click here.
Search: Atripla, Truvada, Emtriva, Gilead, price, increase
Scroll down to comment on this story.
Show comments (13 total)
[Go to top]